Table 1.
Baseline demographic, clinical, and characteristics of patients with coronavirus disease 2019 (COVID-19).
| Baseline Characteristics | COVID-19 Patients with Acute Intracranial Hemorrhage (n = 18) |
|---|---|
| Clinical Parameters | |
| Age (years), median (IQR) | 49.50 (39.25–62.75) |
| Female, n (%) | 9 (50.0) |
| Hypertension, n (%) | 10 (55.6) |
| Diabetes mellitus, n (%) | 4 (22.2) |
| Comorbidities | |
| • cardiovascular, n (%) | 6 (33.3) |
| • neurovascular, n (%) | 1 (5.6) |
| • oncological, n (%) | 4 (22.2) |
| GCS score, median (IQR) | 9 (3–7) |
| Anticoagulation Treatment, n (%) | 8 (44.4) |
| Antiplatelet Treatment, n (%) | 1 (5.6) |
| Time difference between symptom onset to imaging, (days), median (IQR) | 1.5 (0–3) |
| Time difference between admission to imaging, (days), median (IQR) | 11 (9–29.4) |
| Laboratory Parameters | |
| Lactate dehydrogenase, median (U/L), median (IQR) | 483.50 (278–738.5) |
| Creatinine (mg/dL), median (IQR) | 2.06 (1.45–2.81) |
| C-reactive protein (mg/L), median (IQR) | 239.8 (145–377.14) |
| Platelet (103/µL), median (IQR) | 218.0 (108.5–445.25) |
| White blood cells [×109/L], median (IQR) | 8.5 (2.9–28.2) |
| D-dimer (µg/L), median (IQR) | 8.8 (7.0–11.5) |
| COVID-19 Symptoms | |
| Neurological symptoms first, n (%) | 2 (11.1) |
| Respiratory symptoms first, n (%) | 16 (88.9) |
| COVID-19 Classification | |
| Mild lung infection, n (%) | 1 (5.6) |
| Regular lung infection, n (%) | 1 (5.6) |
| Severe lung infection, n (%) | 1 (5.6) |
| Critical lung infection, n (%) | 15 (83.3) |
| Procedure Process and Results | |
| Craniectomy, n (%) | 1 (5.6) |
| EVD, n (%) | 1 (5.6) |
| ECMO, n (%) | 8 (44.4) |
| Ventilation, n (%) | 13 (72.2) |
| Sepsis, n (%) | 8 (44.4) |
| mRS, n (%) | |
| • 0–3 | 0 (0) |
| • 4–6 | 18 (100) |
Legend: Comparison of baseline demographic, clinical characteristics in patients with COVID-19 and an acute intracranial hemorrhage. ECMO indicates extracorporeal membrane oxygenation; EVD, extraventricular drainage; GCS, Galsgow Coma Scale.